Formosa Pharmaceuticals, Inc.
Research Formosa Pharmaceuticals, Inc. (6838.TW) on Bullrun: market cap TWD 3.83B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6838.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 3.83B
- Financial periodQ2 2026
- RevenueTWD 3.03M
- Net income-TWD 67.63M
- Free cash flow-TWD 158.41M
- Gross margin-153.3%
Valuation Snapshot
latest market cap is TWD 3.83B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 3.83B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction;
ETFs that hold Formosa Pharmaceuticals, Inc.
US-listed ETFs
Formosa Pharmaceuticals, Inc. is held by 3 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.01% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Formosa Pharmaceuticals, Inc.'s market cap?
Formosa Pharmaceuticals, Inc.'s market capitalization is TWD 3.83B.
What does Formosa Pharmaceuticals, Inc. do?
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer.